FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205261979> ?p ?o ?g. }

• W4205261979 endingPage "S68" @default.
• W4205261979 startingPage "S68" @default.
• W4205261979 abstract "Spinal muscular atrophies (SMA) are clinically and genetically heterogenous inherited orphan diseases leading to progressive spinal motoneurons degeneration and loss of function. Risdiplam and nusinersen are both authorized in Russia for pathogenic SMA treatment. The aim of the study was to perform health-economic evaluation of risdiplam in patients with SMA. The health-economic analysis was done in accordance with local Russian regulation. Due to absence of direct or indirect comparative effectiveness studies between risdiplam and nusinersen the cost-minimizing analysis was used. We accounted for direct medical costs of pathogenic treatment of SMA (risdiplam and nusinersen), adverse events correction and supportive care. Calculations of dosages and drugs direct medical costs were done based on the weight distribution of children and adolescent population in Russia. Decision tree analysis was used. In budget impact analysis the rise of risdiplam share from 0% to 8,5% was modelled at the time horizon – 3 years. The data from national SMA register was used to accurate calculation of the patient’s population size. Probabilistic sensitivity analysis was done changing the drug’s costs, size of patient’s population and the share of risdiplam and nusinersen. Total direct medical costs for risdiplam (53 372 153 RUR for one patient in 3 years) were by 21,1% (14 968 427,82 RUR) lower comparing to nusinersen. The most pronounced difference in favor of risdiplam (41,9%) was during first treatment year. The rise of risdiplam share from 0% to 8,5% during 3 years is associated with lower budget costs by 13,9% in 3 years. Probabilistic sensitivity analysis confirmed the results of the main scenario. Risdiplam is economically more effective comparing to nusinersen in Russian economic conditions, because having comparable effectiveness it’s use is associated with lower direct medical costs." @default.
• W4205261979 created "2022-01-26" @default.
• W4205261979 creator A5000058509 @default.
• W4205261979 creator A5014311987 @default.
• W4205261979 creator A5014746824 @default.
• W4205261979 creator A5029676090 @default.
• W4205261979 creator A5054362085 @default.
• W4205261979 date "2022-01-01" @default.
• W4205261979 modified "2023-09-27" @default.
• W4205261979 title "POSB42 The Health-Economic Evaluation of Risdiplam in Patients with Spinal Muscular Atrophy" @default.
• W4205261979 doi "https://doi.org/10.1016/j.jval.2021.11.315" @default.
• W4205261979 hasPublicationYear "2022" @default.
• W4205261979 type Work @default.
• W4205261979 citedByCount "0" @default.
• W4205261979 crossrefType "journal-article" @default.
• W4205261979 hasAuthorship W4205261979A5000058509 @default.
• W4205261979 hasAuthorship W4205261979A5014311987 @default.
• W4205261979 hasAuthorship W4205261979A5014746824 @default.
• W4205261979 hasAuthorship W4205261979A5029676090 @default.
• W4205261979 hasAuthorship W4205261979A5054362085 @default.
• W4205261979 hasBestOaLocation W42052619791 @default.
• W4205261979 hasConcept C11413529 @default.
• W4205261979 hasConcept C141071460 @default.
• W4205261979 hasConcept C161921814 @default.
• W4205261979 hasConcept C187212893 @default.
• W4205261979 hasConcept C2778558090 @default.
• W4205261979 hasConcept C2908647359 @default.
• W4205261979 hasConcept C41008148 @default.
• W4205261979 hasConcept C71924100 @default.
• W4205261979 hasConcept C99454951 @default.
• W4205261979 hasConceptScore W4205261979C11413529 @default.
• W4205261979 hasConceptScore W4205261979C141071460 @default.
• W4205261979 hasConceptScore W4205261979C161921814 @default.
• W4205261979 hasConceptScore W4205261979C187212893 @default.
• W4205261979 hasConceptScore W4205261979C2778558090 @default.
• W4205261979 hasConceptScore W4205261979C2908647359 @default.
• W4205261979 hasConceptScore W4205261979C41008148 @default.
• W4205261979 hasConceptScore W4205261979C71924100 @default.
• W4205261979 hasConceptScore W4205261979C99454951 @default.
• W4205261979 hasIssue "1" @default.
• W4205261979 hasLocation W42052619791 @default.
• W4205261979 hasOpenAccess W4205261979 @default.
• W4205261979 hasPrimaryLocation W42052619791 @default.
• W4205261979 hasRelatedWork W2062455150 @default.
• W4205261979 hasRelatedWork W2153861281 @default.
• W4205261979 hasRelatedWork W2215953814 @default.
• W4205261979 hasRelatedWork W2886774428 @default.
• W4205261979 hasRelatedWork W2976036786 @default.
• W4205261979 hasRelatedWork W3093669834 @default.
• W4205261979 hasRelatedWork W3136340635 @default.
• W4205261979 hasRelatedWork W3193767101 @default.
• W4205261979 hasRelatedWork W4205452488 @default.
• W4205261979 hasRelatedWork W4283376240 @default.
• W4205261979 hasVolume "25" @default.
• W4205261979 isParatext "false" @default.
• W4205261979 isRetracted "false" @default.
• W4205261979 workType "article" @default.